Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
September 05, 2023 01:00 ET
|
Addex Therapeutics
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
September 04, 2023 01:00 ET
|
Addex Therapeutics
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-stroke functional recovery Ad Hoc Announcement Pursuant to...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 10, 2023 01:00 ET
|
Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendationIndivior GABAB PAM collaboration extended to June 2024...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
August 04, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
August 03, 2023 01:00 ET
|
Addex Therapeutics
Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3, 2023 - Addex...
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
July 24, 2023 01:00 ET
|
Addex Therapeutics
Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva,...
Addex Increases Issued Share Capital to Create Treasury Shares
June 15, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 01, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
May 18, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
May 11, 2023 01:00 ET
|
Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc...